UY39593A - Tratamiento para tumores sólidos malignos - Google Patents
Tratamiento para tumores sólidos malignosInfo
- Publication number
- UY39593A UY39593A UY0001039593A UY39593A UY39593A UY 39593 A UY39593 A UY 39593A UY 0001039593 A UY0001039593 A UY 0001039593A UY 39593 A UY39593 A UY 39593A UY 39593 A UY39593 A UY 39593A
- Authority
- UY
- Uruguay
- Prior art keywords
- solid tumors
- treatment
- malignant solid
- subject
- malignant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento, se describe un método para tratar tumores sólidos en un sujeto. El método en general incluye administrar una cantidad terapéuticamente eficaz de poziotinib o una sal farmacéuticamente aceptable del mismo a un sujeto que lo necesite.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063199445P | 2020-12-29 | 2020-12-29 | |
US202163166748P | 2021-03-26 | 2021-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39593A true UY39593A (es) | 2022-07-29 |
Family
ID=82259660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039593A UY39593A (es) | 2020-12-29 | 2021-12-28 | Tratamiento para tumores sólidos malignos |
Country Status (3)
Country | Link |
---|---|
TW (1) | TW202237122A (es) |
UY (1) | UY39593A (es) |
WO (1) | WO2022147150A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210145161A (ko) * | 2019-03-29 | 2021-12-01 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Her2 엑손 21 삽입물을 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
SG11202110669WA (en) * | 2019-03-29 | 2021-10-28 | Univ Texas | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
UY39342A (es) * | 2020-07-27 | 2022-02-25 | Spectrum Pharmaceuticals Inc | Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas |
-
2021
- 2021-12-28 UY UY0001039593A patent/UY39593A/es unknown
- 2021-12-29 WO PCT/US2021/065545 patent/WO2022147150A1/en active Application Filing
- 2021-12-29 TW TW110149314A patent/TW202237122A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW202237122A (zh) | 2022-10-01 |
WO2022147150A1 (en) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002267A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945) | |
CO2021015318A2 (es) | Compuestos y métodos para el tratamiento de covid-19 | |
ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
CL2021002533A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras | |
WO2018102687A3 (en) | Combination therapy for treating cancer | |
CL2022003511A1 (es) | Inhibidores de alk2 para el tratamiento de la anemia. | |
CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
AR119159A1 (es) | Tratamientos de angioedema | |
CL2023000857A1 (es) | Inhibidores line-1 para tratar la enfermedad | |
CL2022000781A1 (es) | Tratamientos cognitivos medicinales | |
CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
EA202190457A1 (ru) | Конъюгаты для применения в способах лечения рака | |
MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
UY39593A (es) | Tratamiento para tumores sólidos malignos | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
AR118933A1 (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres | |
AR122301A1 (es) | Métodos para tratar los tumores del estroma gastrointestinal | |
AR117290A1 (es) | Enfoque de tratamiento de cáncer mediante inmunomodulación |